• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Led by Cigna, Omada Health Nabs $50M to Expand Digital Therapeutics for Chronic Disease

by HITC Staff 06/14/2017 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Led by Cigna, Omada Health Nabs $50M to Expand Digital Therapeutics for Chronic Disease

Omada Health, a digital health company that helps health plans and employers tackle type 2 diabetes and heart disease in the most engaging, effective, and scalable way possible has raised $50 million in funding led by Cigna. The round also included participation and U.S. Venture Partners, Andreessen Horowitz, Norwest Venture Partners, Humana, Kaiser Permanente Ventures, Providence Ventures, dRx Capital, GE Ventures, Civilization Ventures and Sanofi Genzyme BioVentures.

Omada also announced that Cigna is expanding its non-exclusive commercial partnership with Omada, adding the recognized Omada Program to Cigna’s suite of health improvement services. This will enable eligible Cigna-administered health plan customers may have no-cost access to Omada’s digital intensive behavioral counseling platform as a fully covered preventive benefit in the carrier’s health improvement program portfolio. The Cigna-Omada Initiative will incorporate Omada’s data-driven, evidence-based digital behavioral counseling program and be available to Cigna customers with prediabetes, as well as those at elevated risk of chronic conditions such as heart disease and hypertension.

Cigna initially evaluated Omada’s digital behavior change program in 2015, with positive results to date, and expressed plans to expand availability in the future. For Cigna, the continued partnership with Omada Health is consistent with Cigna’s focus on preventing diabetes, improving health, and driving better clinical and health economic outcomes for its members.

“Cigna is one of the most forward-thinking health service companies in the United States,” said Omada CEO Sean Duffy in a statement. “We love when our commercial partners invest, and Cigna’s lead on this fundraising round is further validation that Omada’s behavior change approach to chronic disease prevention is driving real results in the real world. We look forward to working with the Cigna leadership to deliver personalized, adaptable chronic disease prevention to their membership. As Omada expands further into the health plan and health system space, we are fortunate to be working with some of the most well-established and innovative companies in the healthcare industry.”

 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Digital Therapeutics, Omada Health

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |